search

Active clinical trials for "Ovarian Neoplasms"

Results 591-600 of 2005

Registry Platform Ovarian and Endometrial Cancer

Ovarian CancerEndometrial Cancer7 more

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.

Recruiting10 enrollment criteria

Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Colorectal NeoplasmsColorectal Cancer4 more

By obtaining clinical specimens from participants with triple negative breast cancer (TNBC), colorectal cancer (CRC), high grade serous ovarian cancer (HGSOC), and other select tumor types to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with personalized cancer treatment options

Recruiting22 enrollment criteria

KOrean Borderline Ovarian Tumor (KOBOT) Registry

Ovarian Neoplasms

The aim of this study is to collect data on Korean patients with borderline ovarian tumors.

Recruiting3 enrollment criteria

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

Ovarian Cancer Prevention

While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent it.

Active24 enrollment criteria

Prospective Validation of the ADNEX Model for Discrimination Between Benign and Malignant Adnexal...

Adnexal MassAdnexal Tumor2 more

Prospective Validation of the ADNEX Model for discrimination between benign and malignant adnexal masses in pregnancy: International Ovarian Tumour Analysis in pregnancy study (p-IOTA)

Recruiting9 enrollment criteria

CADx - Radiomics to Distinguish the Origin of Ovarian Tumors

Ovarian Cancer

In women with an ovarian tumor, it is often unclear whether the tumor is benign or malignant. To differentiate, tumor markers (CA125 and CEA), a transvaginal ultrasound and, depending on the ultrasound image and the CA125 concentration, a CT scan are performed. The quality of radiological imaging in diagnosing abdominal pathology is often not accurate enough, making additional interventions no-dig for proper classification and interpretation of the tumor. Objective: To improve accuracy for distinguishing benign from malignant disease in patients presenting with an ovarian mass by using a computer aided detection algorithm.

Recruiting5 enrollment criteria

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

Ovarian CancerHigh Grade Ovarian Serous

The researchers are doing this study to find out whether the researchers can combine information provided by PET/MRI scans with information from tests on blood and tissue samples to develop a very detailed description (profile) of high-grade serous ovarian carcinoma (HGSOC), which could improve our ability to treat this disease. The study researchers will use computers to analyze the combined results of the imaging tests and the genetic and immune system tests on the tumor samples. The study researchers think that this information will help them more accurately predict the way tumors respond to treatment, which may improve their ability to individualize treatments for this disease.

Active19 enrollment criteria

Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian...

Ovarian Carcinoma

Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Recruiting3 enrollment criteria

Chromosomal Instability in Ovarian Cancer

Epithelial Ovarian CancerHigh-grade Serous Ovarian Carcinoma6 more

Chromosomal instability (CIN) refers to the ongoing genomic change, which involves the amplification or deletion of chromosome copy number or structure. The changes rang from point mutation to small-scale genomic change and even the change of whole chromosome number. It has been reported that the characteristics of genomic rearrangement can be used as a marker of clinical outcome of high-grade serous ovarian cancer, and specific genomic rearrangement are related to the poor prognosis. In noninvasive gene detection with low coverage, patients diagnosed with ovarian cancer have deteriorating progression-free and overall survivals regardless of the tumor stage when somatic copy number distortion (sCNA) exceeds the threshold in plasma. The detection rate of sCNA increased along with the tumor stage. We enrolled those as our target patients, who are diagnosed with high-grade serous ovarian cancer and willing to take part in. The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment. Our aim is to explore the application of CIN in peripheral tumor DNA in the detection of minimal residual lesions (MRD) after primary treatment and recurrence monitoring.

Recruiting6 enrollment criteria

Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian...

Ovarian Cancer

The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

Recruiting8 enrollment criteria
1...596061...201

Need Help? Contact our team!


We'll reach out to this number within 24 hrs